Ligand Pharmaceuticals Inc LGND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LGND is a good fit for your portfolio.
News
-
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
-
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
-
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
-
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
-
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
-
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
-
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Trading Information
- Previous Close Price
- $79.87
- Day Range
- $79.00–81.52
- 52-Week Range
- $49.28–94.23
- Bid/Ask
- $81.11 / $81.42
- Market Cap
- $1.44 Bil
- Volume/Avg
- 75,707 / 177,546
Key Statistics
- Price/Earnings (Normalized)
- 14.12
- Price/Sales
- 11.02
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 58
- Website
- https://www.ligand.com
Comparables
Valuation
|
Metric
|
LGND
|
EGRX
|
CRNX
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.12 | 1.06 | — |
Price/Book Value | 2.04 | 0.26 | 5.80 |
Price/Sales | 11.02 | 0.25 | 664.21 |
Price/Cash Flow | 17.23 | 1.35 | — |
Price/Earnings
LGND
EGRX
CRNX
Financial Strength
|
Metric
|
LGND
|
EGRX
|
CRNX
|
|---|---|---|---|
Quick Ratio | 12.49 | 1.52 | 12.92 |
Current Ratio | 14.15 | 2.16 | 13.07 |
Interest Coverage | 86.29 | 5.39 | — |
Quick Ratio
LGND
EGRX
CRNX
Profitability
|
Metric
|
LGND
|
EGRX
|
CRNX
|
|---|---|---|---|
Return on Assets (Normalized) | 9.22% | 6.32% | −38.81% |
Return on Equity (Normalized) | 10.93% | 10.51% | −44.79% |
Return on Invested Capital (Normalized) | 9.44% | 9.73% | −45.62% |
Return on Assets
LGND
EGRX
CRNX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mhlndxvcyj | Dckw | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lkzmghrb | Ggdczl | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Stsfbqhr | Swrmlcr | $98.6 Bil | |
MRNA
| Moderna Inc | Xcqfxhs | Pgvd | $41.0 Bil | |
ARGX
| argenx SE ADR | Xrsfknnx | Sbz | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Wdpzpxpwy | Ykzf | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rbhggfxk | Gshrdd | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Htwtcllr | Czmmmc | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ljmkntwcd | Jwkmff | $12.6 Bil | |
INCY
| Incyte Corp | Hrkwydpbb | Htctdr | $12.0 Bil |